BioLineRx (BLRX) director Raphael Hofstein reports extensive stock options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioLineRx Ltd. director Raphael Hofstein filed an initial ownership report showing he holds several employee stock options over the company’s ordinary shares. This Form 3 does not report new purchases or sales, but lists option grants previously awarded under the company’s 2003 Amended and Restated Share Incentive Plan.
The disclosed positions include options exercisable at prices such as $0.8370, $0.9200, and as low as $0.0520 per share, with expiration dates ranging from July 2026 to August 2034. Footnotes state that most grants are already fully vested, while a large grant covering 2,055,000 underlying shares at $0.0520 has 856,200 options vested and 1,198,800 scheduled to vest in seven equal quarterly installments, contingent on his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Hofstein Raphael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 49,800 shares (Direct)
Footnotes (1)
- Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.
Key Figures
Option exercise price: $0.8370 per share
Option exercise price: $0.9200 per share
Option exercise price: $0.3560 per share
+4 more
7 metrics
Option exercise price
$0.8370 per share
Employee stock option expiring July 5, 2026 over 49,800 underlying ordinary shares
Option exercise price
$0.9200 per share
Employee stock option expiring July 5, 2027 over 19,800 underlying ordinary shares
Option exercise price
$0.3560 per share
Employee stock option expiring July 2, 2029 over 199,800 underlying ordinary shares
Option exercise price
$0.0850 per share
Employee stock option expiring July 3, 2032 over 1,080,000 underlying ordinary shares
Option exercise price
$0.0810 per share
Employee stock option expiring July 3, 2033 over 360,000 underlying ordinary shares
Largest grant exercise price
$0.0520 per share
Employee stock option expiring August 14, 2034 over 2,055,000 underlying ordinary shares
Partially vested portion
856,200 options vested
From October 1, 2024 grant; remaining 1,198,800 vest in seven quarterly installments
Key Terms
Employee Stock Option (Right to Buy), 2003 Amended and Restated Share Incentive Plan, Section 102 of the Israeli Tax Ordinance, trustee, +1 more
5 terms
Employee Stock Option (Right to Buy) financial
"security_title: "Employee Stock Option (Right to Buy)""
Section 102 of the Israeli Tax Ordinance financial
"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance..."
trustee financial
"securities issued ... must be registered in the name of a trustee."
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
fully vested financial
"This option grant is fully vested as of this date."
FAQ
What does Raphael Hofstein’s Form 3 for BioLineRx (BLRX) disclose?
The Form 3 discloses Hofstein’s existing stock option holdings in BioLineRx. It lists multiple employee stock option grants over ordinary shares, with specified exercise prices and expiration dates, rather than reporting new share purchases or sales. These options were granted under the 2003 Amended and Restated Share Incentive Plan.
Are Raphael Hofstein’s BioLineRx (BLRX) stock options already vested?
Most of Hofstein’s option grants are fully vested, but one large grant is partly unvested. Footnotes explain that grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant has 856,200 options vested and 1,198,800 scheduled to vest in seven quarterly installments.
What are the exercise prices of Hofstein’s BioLineRx (BLRX) stock options?
The disclosed exercise prices range from $0.0520 to $0.9200 per share. Earlier grants carry higher exercise prices such as $0.8370 and $0.9200, while later grants include lower prices like $0.0850, $0.0810, and a large grant at $0.0520 per ordinary share.
When do Raphael Hofstein’s BioLineRx (BLRX) stock options expire?
The options expire between July 2026 and August 2034. Individual grants show expiration dates including July 5, 2026, July 5, 2027, July 2 of 2029–2031, July 3 of 2032–2033, and an August 14, 2034 expiration for the largest, most recent grant.
Under which plan were Hofstein’s BioLineRx (BLRX) options granted?
The options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. A footnote clarifies that all the reported employee stock options come from this plan, which governs equity-based compensation awards, including vesting conditions and certain tax-related requirements.
How do Israeli tax rules affect Hofstein’s BioLineRx (BLRX) option grants?
Certain options are held via a trustee to qualify for Israeli tax benefits. A footnote notes that, under Section 102 of the Israeli Tax Ordinance, securities issued under the 2003 Share Incentive Plan must be registered in a trustee’s name to obtain specific employee tax advantages.
Biolinerx